Novartis' Global Innovative siRNA Long-Acting Lipid-lowering Therapy Submitted Clinical Application in China

On June 28, the CDE official website showed that Novartis' siRNA long-acting lipid-lowering drug Inclisiran submitted a clinical application in China and has been accepted and accepted.

Inclisiran is a product of small interfering RNA (siRNA) modified by a sugar molecule called GalNAc. This modified siRNA is more easily absorbed by cells and has higher stability and lasting effect.

As a world's first siRNA lipid-lowering drug, Inclisiran uses the natural process of human RNA interference to combine with the mRNA encoding PCSK9 protein, which reduces the mRNA level and prevents the liver from producing PCSK9 protein through RNA interference, thereby enhancing the ability of liver to clear LDL-C from the blood and achieve LDL-C level reduction.

Inclisiran was first developed by Alnylam pharmaceuticals. Novartis incorporated the drug Inclisiran into its own product line through acquisition.

Analysts at EvaluatePharma had predicted Inclisiran’s annual sales will exceed US$1.5 billion in 2024, and the future sales peak will reach US$2 billion. As sales of the earlier marketed PCSK9 inhibitors (Sanofi's Praluent and Repatha of Amgen) are not as expected, the latecomer Inclisiran is expected to meet the previous market expectations for PCSK9 inhibitors in the industry.

About  the Author:    

Xiaoyaowan, a pharmaceutical industry practitioner, a word carrier in the We-media era focusing on changes of the pharma industry.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.